Open access peer-reviewed chapter

Natural Products as Promising Pharmacological Tools for the Management of Fibromyalgia Symptoms – A Review

Written By

Renan Guedes Brito, Priscila Laise Santos, Marlange Almeida Oliveira, Lícia Tairiny Santos Pina, Angelo Roberto Antoniolli, Jackson Roberto Guedes da Silva Almeida, Laurent Picot, Gokhan Zengin, Jullyana Souza Siqueira Quintans and Lucindo José Quintans Júnior

Submitted: 05 December 2016 Reviewed: 05 June 2017 Published: 20 December 2017

DOI: 10.5772/intechopen.70016

From the Edited Volume

Discussions of Unusual Topics in Fibromyalgia

Edited by William S. Wilke

Chapter metrics overview

1,651 Chapter Downloads

View Full Metrics


Fibromyalgia (FM) is the second most common rheumatologic disorder, affecting 5% of the world population, and has a serious effect on the quality of life of patients, as well as an economic impact through lost workdays. This pain syndrome is a common cause of chronic widespread pain and is characterized by reduced pressure pain thresholds with hyperalgesia and allodynia, nonrestorative sleep, fatigue, cognitive dysfunction, and mood disturbances. The pharmacological treatment strategies for FM include the use of antidepressants, calcium channel modulators, muscle relaxants, and analgesics but have shown limited efficacy and therapeutic adherence. Thus, researchers have been seeking potential substances (new chemical entities or through drug repositioning) that could be used for FM treatment. In this context, natural products (NPs) have been shown to be promising pharmacological tools due to the variety of their pharmacological activity and the number of molecular sites available as possible active targets. Recent clinical and preclinical studies have been conducted to verify the possible applicability of NPs such as essential oils (EOs), plants extracts, terpenes, sapogenins, and alkaloids in the treatment of FM. The results have shown that natural products have an analgesic effect in different animal models of FM, probably by activation of inhibitory descending pathways, such as the periaqueductal gray and rostroventromedial medulla. Natural products and their secondary metabolites could therefore be a promising source for FM management. However, translational studies that seek to validate the preclinical studies are scarce, incipient, and lacking an approach focused on the traditional pharmaceutical market.


  • natural products
  • muscle pain
  • chronic pain
  • fibromyalgia
  • pain

1. Introduction

Fibromyalgia (FM) is a painful syndrome caused by changes in the central nervous system. This syndrome is chronic in nature and is present in about 5% of the world population. Generalized musculoskeletal pain and changes in sensitivity, as well as fatigue in the absence of any organic disease, are presented as clinical aspects. Other important symptoms may manifest in patients with FM such as sleep disturbances and cognitive problems, as well as a variety of psychosomatic symptoms. Patients with FM often complain of tingling, numbness, burning, cutaneous hyperalgesia, momentary pain attacks, and depression [1].

Pathophysiological factors are genetic predisposition, autonomic and emotional dysfunctions, physical or environmental stresses, and neurohormonal and inflammatory dysfunctions [2]. Besides that, ischemia and muscular microtraumas, which result in pain during and after exercise, can be considered favorable for the onset of pain in FM. Elvin et al. [3] studied 10 female fibromyalgic patients and 11 female patients in the control group, using Doppler ultrasound in the infraspinatus muscle during low-intensity exercise. Experimental patients presented muscle ischemia when compared to control patients, perhaps because they evoked reflexes in the muscular sympathetic nervous activity, resulting in vasoconstriction. This may be contributed to pain in FM, which could be resulting from possible microtraumas. An abrupt increase in muscle vascularization during and after dynamic exercise was also observed for patients with FM, which did not occur with static exercise when compared to the control patients. Thus, increased muscle sympathetic nerve activity in the FM group may have resulted in imbalance between vasodilation and sympathetic vasoconstriction.

Areas of the descending pathway of pain, such as the periaqueductal gray (PAG) and rostroventromedial area (RVM), which have mainly opioid and serotonergic activation, respectively, may act in endogenous analgesia. These two areas make connections with the dorsal horn of the spinal cord, modulating the transmission of nociceptive messages [3, 4]. Changes in these areas of the central nervous system (CNS) probably occur due to a neurochemical imbalance, with the glutamatergic, 5-HTergic and opioidergic systems being important targets to control this neurotransmitter fluidity. This results in the classification of FM as a central pain syndrome, also known as “dysfunctional pain,” where there are changes in sensitivity such as allodynia (pain due to a stimulus that normally does not cause pain) and hyperalgesia (increased pain of a stimulus that usually causes pain), without any tissue or nervous injury [5, 6, 7].

Due to the complexity of its pathophysiology, the treatment of FM is very difficult. Only 30% of the medicines used to treat FM have some positive effect. Some drugs have high costs (financial or in terms of side effects), being possible triggers of collateral effects such as nausea, edema, tachycardia, and with poor therapeutic efficacy [1, 2, 8, 9, 10, 11, 12]. In order to better understand the physiopathology as well as to investigate new treatment options for FM, animal models have been developed that mimic some symptoms of this syndrome. Scientists have used a combination of repetitive stimuli applied to the muscle, coupled with stress added to the nociceptive stimuli applied in the muscle to trigger lasting hyperalgesia, which mimics FM (Table 1) [13, 14, 15, 16].

AuthorAnimal modelInductionSimilarities with the clinical conditionLimitations of the model
Sluka, Kalra, Moore [35]Acid saline-induced painTwo injections of acid saline (pH 4; im) separated by 2–5 daysWidespread and generalized hyperalgesia including the bilateral hind limbs, muscles, paws, and viscera, and anxietyIt is not clear if there are comorbidities such as depression, anxiety, fatigue, or sleep disturbances, as in FM. Unlike what is observed in FM, the model is sensitive to opioids intrathecally
Dina, Levine, Green [36]; Dina, Green, Levine [37]Hyperalgesic priming modelAn acute inflammatory insult (carrageenan or IL-6) followed by PGE2 injection into the same muscleLong duration of hyperalgesia may indicate differential processing of muscular or cutaneous pain by peripheral or central pathwaysPharmacological and non-pharmacological treatments for FM or comorbidities, as well as changes in the CNS, have not yet been studied in this model
Yokoyama et al. [38]Fatigue-enhanced muscle painRunning wheel for 2 h followed by two injections of acid saline (pH 5)Muscle fatigue may increase hyperalgesia produced by low-intensity agentsPharmacological and non-pharmacological treatments for FM or comorbidities have not yet been determined
Nagakura et al. [39]Biogenic amine depletion modelRepeated administration of reserpine (1 mg/kg/day, for 3 consecutive days; sc)Animals show signs of comorbidities as depression and anxietyIt is unclear how changes in the serotonergic system contribute to the maintenance of hyperalgesia. All studies so far have been performed only on males. It is not known if there are differences between males and females
Nishiyori et al. [40]Cold stress modelMaintenance in cold room (−3 to +4°C) overnight for 3 days and transfer between normal room temperature (24°C) and a cold room every 30 min during the dayPharmacological treatments directed to FM also have an effect in this model, with the exception of opioids, which are not effective in FM and reduce hyperalgesia in the model citedComorbidities such as anxiety and depression are not developed
Khasar et al. [41]Sound stress modelExposure to pure tones of 5, 11, 15, and 19 kHz, with amplitudes between 20 and 110 dB in random times each minute, lasting from 5 to 10 s, on days 1, 3, and 4Anxiety is developed as comorbidityAll studies so far have been performed only on males. It is not known if there are differences between males and females

Table 1.

Summary of major animal models of fibromyalgia.

Note: CNS, central nervous system; FM, fibromyalgia.

In the search for new sources of more effective drugs with fewer side effects, scientists have been focusing on the study of different pharmacological approaches including natural products (NPs) due to their promising effects on the CNS. NPs are considered the main source of new chemical entities in the search for new medicines and may be fundamental to the discovery of new drugs for diseases or syndromes that still do not respond adequately to the current available treatments. In this context, an important approach to discover new painkillers has been developed with NPs such as medicinal plants or their secondary metabolites that could modulate painful conditions, including FM [17].

Medicinal plants (MPs) are natural products that have been used in the control of several diseases by the world’s population for thousands of years. Popular knowledge about the use of these plants has directed scientists to conduct new research seeking drugs that act on specific targets or multiple molecular sites such as the pathophysiology of FM usually presents [18, 19]. Many drugs that are commonly used in clinical treatment are derived directly or indirectly from MPs and include analgesics such as aspirin (anti-inflammatory nonsteroidal derived from salicylic acid, which was initially extracted from Salix alba) and morphine (opioid analgesic derived from Papaver somniferum) [20]. As evidence of the importance of natural products, between 2005 and 2010, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved 19 medicines derived from NPs, including trabectedin (Yondelis™) and cannabidiol (Sativex®), for cancer and pain treatment, respectively [21, 22]. Moreover, the growing number of patents to protect new formulations containing NPs demonstrates the importance of these compounds [23].

In relation to FM, some classes of bioactive compounds extracted from medicinal plants have presented analgesic activity described in the literature, such as essential oils [24, 25, 26], extracts [27, 28], monoterpenes [29, 30, 31], sesquiterpenes [32], saponins [33], and alkaloids (Figure 1 and Table 2) [34].

Figure 1.

General structures of different categories of bioactive plant compounds studied for the treatment of FM: alkaloids (A1 and A2); monoterpenes (B); sesquiterpenes (C); and triterpenes, saponins, and steroids (D) (adapted from Azmir et al. [42]).

Natural productDose/routeType of studySampleMolecular mechanismReferences
Essential oils
Hyptis pectinata0.3 ml/mouse (5%); scPreclinicalMale Swiss mice (n = 8/group)Opioid, serotoninergic, cholinergic, and reduction of SP, with involvement in the descending pain pathwayQuintans-Júnior et al. [24]
Ocimum basilicum25, 50, and 100 mg/kg; poPreclinicalMale Swiss mice (n = 8/group)Opioid, glutamatergic, TRPV1, and reduction of SP, with involvement in the descending pain pathwayNascimento et al. [25]
O24™Not described; toClinical133 subjects of either sexStimulation of A-beta sensory fibers and inhibition of bradykinin, histamine, and prostaglandinsKo et al. [26]
Plant extracts
Phyllanthus amarus and Phyllanthus fraternus400 mg/kg; ipPreclinicalMale Wistar rats (n = 5/group)OpioidChopade and Sayyad [27]
Ginkgo biloba200 mg/day; poClinical25 subjects of either sexAntioxidantLister et al. [28]
Linalool25 mg/kg; poPreclinicalMale Swiss mice (n = 8/group)Opioid, glutamatergic, and blocking of neuronal excitabilityNascimento et al. [29]
Citronellal50 mg/kg; poPreclinicalMale Swiss mice (n = 7/group)Opioid, glutamatergic, SP pathway, TRPV1 receptor, involvement in the descending pain pathway, and blocking of sodium channelsSantos et al. [30]
α-Terpineol25, 50, and 100 mg/kg; poPreclinicalMale Swiss mice (n = 8/group)Opioid, serotoninergic, glutamatergic, TRPV1, and reduction of SP, with involvement in the descending pain pathwayOliveira et al. [31]
β-Caryophyllene10 and 20 mg/kg; poPreclinicalMale Swiss mice (n = 8/group)Opioid and cannabinoidQuintans-Júnior et al. [32]
Hecogenin acetate20 mg/kg; poPreclinicalMale Swiss mice (n = 8/group)Opioid, SP, ATP-sensitive K (+) channel, with involvement in the descending pain pathwayQuintans et al. [33]
Capsaicin0.075% (3 times/day); toClinical126 women and 4 menTRPV1 and reduction of SPCasanueva et al. [34]

Table 2.

Summary of studies involving bioatctive compounds aimed at the treatment of fibromyalgia and their main mechanisms of action.

*All preclinical studies used the chronic muscle pain model induced by acid saline.

Note: ATP, adenosine triphosphate; ip, intraperitoneal; po, oral administration; sc, subcutaneous; SP, substance P; to, topically; TRPV1, transient receptor potential vanilloid 1.


2. Pharmacology of bioactive compounds

Bioactive compounds, produced by plants, are designated secondary metabolites. Metabolites can be divided into primary and secondary. Primary metabolites are those involved in growth and development, such as carbohydrates, amino acids, proteins, and lipids, while secondary metabolites, which often have unusual chemical structures, are not required for primary metabolic processes and are believed to support plant survival with respect to local challenges. Thus, the production of secondary metabolites of a given species will be related to their need for survival. Among the secondary metabolites, some compounds have an effect on biological systems, being considered bioactive, which defines them as secondary metabolites of plants that induce pharmacological or toxic effects in humans or animals [42].

Bioactive compounds can be extracted from various parts of the plant, such as the leaves, seeds, flowers, bark, roots, and fruits [43]. These compounds form the essential oil of the plant, resin, or other plant products, which can be extracted in a concentrated form (containing secondary metabolites) or by means of solvents, such as water, ethanol, methanol, chloroform, dichloromethane, ether, and acetone [42]. The best solvent or extraction procedure will depend on the botanical material to be used as well as of the type of secondary metabolites being obtained. In addition, various substances can be isolated from the essential oil or chemical extracts, such as terpenes, flavonoids, alkaloid, and steroids that already have some known property that can be used in the treatment of FM [43].

2.1. Essential oils

Essential oils (EOs) are derived from the secondary metabolism of aromatic plants and are mainly terpene compounds. They are volatile and usually have a strong and characteristic smell. In nature, they perform plant protection functions against predators and help attract certain animals for pollination. In industry, they are used for numerous purposes including in perfume, as antiseptics, and food preservatives but also have numerous pharmacological properties [44]. They are mixtures and may contain 20–60 compounds (or more) in varying concentrations. Usually, each EO is characterized by its major components, which may be number two or three and usually be between 20 and 70% of the oil [45].

Although the biological effect of EOs are thought to be due to the major components which define their pharmacological profiles, synergism between the molecules present in each oil, even those that are in a smaller quantity, can modulate the effects of the major components [45].

2.2. Plant extracts

Based on non-pharmacological studies and holistic or alternative medicine with the use of medicinal plants (and related products), several researchers have sought to evaluate the effects of materials obtained through NPs in clinical and preclinical studies. This research has been based on the popular and potentially dangerous belief given the chemical diversity of NPs that “what is natural, cannot do you harm.” The innovative pharmacological effects that these products are able to produce are promising but due to possible side effects remain challenging at the same time [50, 51, 52]. One way to evaluate possible pharmacological effects and examine their use in folk medicine is to study plant extracts obtained through the use of several solvents [53, 54, 55]. The extraction of biological products using solvents is mainly used with fragile or delicate flower materials, which do not tolerate the heat of steam distillation. Examples of solvents which may be used to produce plant extracts are acetone, hexane, ether, methanol, or ethanol [43]. These extracts, in turn, can have a limited use due to their high viscosity, facilitating aggregation and precipitation, or the presence of proteins that induce false results, causing better ways of obtaining and fractionating the crude extracts to be sought [54].

2.3. Terpenes

Terpenes are the largest group of secondary metabolites obtained through natural products, being made from isoprene units (five carbons (C5)). They exhibit a wide variety of structures and are the most common class of chemical compounds found in essential oils [43, 46, 47, 48]. Essential oils contain mainly monoterpenes (C10) and sesquiterpenes (C15), which are generally hydrocarbons of the general formula (C5H8)n. At a lower concentration, they are present in essential oils as diterpenes (C20), triterpenes (C30), and tetraterpenes (C40), which are larger molecules. Terpenoids are oxygen compounds that can be derived from terpenes. These compounds may present predominantly as phenols, monoterpene alcohol, sesquiterpene alcohol, aldehydes, ketones, esters, oxides, lactones, and ethers [43].

Although monoterpenes are smaller molecules than sesquiterpenes, the structure and functional properties of these groups are similar [43, 49]. Most monoterpenes are colorless, volatile, and lipophilic, which promote greater penetration through the membrane [49]. Among the activities already described, the antinociceptive properties of these compounds have received a lot of attention [50, 51, 52].

2.4. Saponin

Triterpenoid or steroidal aglycones linked to portions of oligosaccharides are called saponins. Saponins are amphipathic because of the combination of the aglycone, having hydrophobic characteristics, and sugar molecules, with a hydrophilic profile. These compounds have been studied for use in the pharmaceutical, cosmetic, agronomic, and food industries [53]. Saponins present some therapeutic activities including powerful membrane-permeabilizing agents with hypocholesterolemic, immunostimulatory, anti-inflammatory, antimicrobial, anticarcinogenic, antiprotozoan, molluscicides, and antioxidant properties [54]. The majority of plant species-producing saponins are dicotyledonous and accumulate mainly triterpenoid saponins. The monocotyledon type mainly synthesizes saponins of the steroidal type [55].

2.5. Alkaloids

Alkaloids are complex compounds that contain nitrogen. These compounds have been used in the production of various drugs, such as metronidazole (derived from azomycin) and bedaquiline (derived from quinolone) [56, 57, 58, 59, 60]. Capsaicin is an alkaloid derived from hot chili peppers from the Capsicum. This alkaloid interacts with afferent nociceptors by means of the vanilloid receptors, resulting in increased sensitivity, which is perceived as pruritus, stinging, or burning. This happens due to selective activation of type C afferent fibers, release of substance P, and cutaneous vasodilation. Capsaicin-based topical creams have been used in the treatment of painful disorders such as musculoskeletal or neuropathic disorders, probably functioning by depletion of substance P in the afferent nerve endings [34, 61, 62, 63].


3. Preclinical studies

Recently, Quintans-Júnior et al. [24] evaluated pretreatment with the EO from Hyptis pectinata loaded in a nanoemulsion thermoreversible gel in an animal model of noninflammatory chronic muscular pain, an experimental model for FM. This pharmaceutical formulation containing EO and Pluronic F127-based hydrogel produced a long-lasting and consistent anti-hyperalgesic effect for 10 days after a single subcutaneous application, which was reversed by naloxone (opioid antagonist) and methysergide (serotoninergic antagonist). In addition, the formulation produced a significant reduction in substance P (SP) levels in the spinal cord. Moreover, it was also shown to increase neuron activation, by Fos protein expression, in the periaqueductal gray (PAG), the nucleus raphe magnus (NRM), and the locus coeruleus (LC), the CNS areas reported to be involved in the descending pathway of pain, so it appears that the formulation acts by improving the endogenous analgesia mechanism (Figure 3). Other studies have demonstrated that H. pectinata essential oil exhibits antinociceptive effects, probably mediated by the opioid and cholinergic receptors [64, 65].

Nascimento et al. [25] demonstrated in the same FM animal model that Ocimum basilicum essential oil, rich in monoterpenes such as linalool, has an important anti-hyperalgesic profile when complexed or noncomplexed with β-cyclodextrin (β-CD). Moreover, the complexed oil produced a long-lasting anti-hyperalgesic effect when compared to the oil alone, demonstrating that the complexation process allows greater stability and bioavailability of the oil or its main compounds, such as monoterpenes. In this paper, the authors also assessed Fos protein expression in the brains of mice and found that this oil promoted the activation of the PAG, NRM, and LC, which are encephalic regions that participate in the antinociceptive effect by the activation of the pain inhibitory descending pathway.

The results obtained for the O. basilicum essential oil may be due to its action on the inhibition of SP or through blocking the neurokinin-1 receptor and the vanilloid receptor (TRPV1). Indeed, this oil also acts by glutamatergic system inhibition or by the inhibition of inflammatory pathways, because it was able to produce a reduction in orofacial nociception when caused by formalin, capsaicin, and glutamate in mice [66]. Furthermore, when assessed using an electrophysiological approach, this oil was able to inhibit an orthodromic response in the dentate hippocampal gyrus, similar to DNQX (a glutamatergic drug), an AMPA and kainate receptor antagonist. In addition, another study carried out by Venâncio et al. [67] demonstrated that the peripheral and central antinociceptive effects of O. basilicum essential oil are related to the inhibition of the biosynthesis of pain mediators, such as prostaglandins and prostacyclins, and its ability to interact with opioid receptors.

Some studies using plant extracts for the treatment of FM have been performed. Chopade and Sayyad [27] used aqueous, methanolic, hydromethanolic, and hydroethanolic extracts of the genus Phyllanthus in an animal model of FM induced by acid saline. It was observed that the extract was able to reduce hyperalgesia without causing tolerance. Extracts of these plants have shown an antinociceptive effect, including in the hot-plate test [68]. In addition, there are indications these extracts depressed the CNS without apparently causing nervous toxicity or altering motor coordination, which may have corroborated with the anti-hyperalgesic effect obtained in the FM animal model [69].

The variability of the pharmacological mechanisms of terpenes and related compounds is shown in Figure 2, especially when incorporated into pharmaceutical formulations which improve their pharmacological properties. Moreover, β-caryophyllene, a major compound of H. pectinata leaf essential oil (HpEO), complexed with β-cyclodextrin decreased Fos protein expression in the superficial dorsal horn, which seems to involve the descending inhibitory pain system in an animal model of FM (Figure 2(C)). Germacrene D, another major component of HpEO, has a strong interaction with the μ-opioid receptor (Figure 2(B)). A more interesting aspect was that when the HpEO was incorporated in a nanoemulsion thermoreversible pluronic F127-based hydrogel, it produced a long-lasting and consistent anti-hyperalgesic effect (Figure 2(A)), suggesting that essential oils and their major components are promising tools for managing FM.

Figure 2.

(A) Effect of nanoemulsion pharmaceutical formulation containing Hyptis pectinata leaf essential oil (NE-EOH; sc), tramadol (TRM, 10 mg/kg; ip), or vehicle (sc) on mechanical sensitivity induced by acidic saline in mice. Each point represents the mean ± SEM (n = 8, per group) of the ipsilateral paw withdrawal threshold. *p < 0.05 and **p < 0.01 vs. control group (ANOVA followed by Tukey’s test). (B) Hydrophobic map of germacrene D (a major compound of Hyptis pectinata leaf essential oil) and μ-opioid receptor (μ-OR). Blue, hydrophobic region; red, hydrophilic region. (C) Fos-positive neurons in the lumbar spinal cord lamina I. Vehicle or β-caryophyllene-β-cyclodextrin (20 mg/kg) was administered orally, and, after 90 min, the animals were perfused (adapted from Quintans-Júnior et al. [25, 33]).

Some studies involving the effects of monoterpenes in FM experimental models have been undertaken due to their possible molecular effects on pain (Figure 3) [52]. Nascimento et al. [29] used linalool (Figure 4), a monoterpene present in plant species of the family Lamiaceae, complexed and noncomplexed in β-CD, in an animal model of FM and observed that both formulations had an anti-hyperalgesic effect, with the complexed form being more effective and producing a longer-lasting effect (for 24 h after administration). Previous studies have shown the analgesic effect of linalool on acute central nociception (hot plate), visceral (acetic acid) [70] and chronic pain models of neuropathic origin [71, 72], and the opioid and glutamatergic systems probably being involved in this action [73]. Moreover, linalool was able to reduce the action potential amplitude assessed using an isolated nerve in the single sucrose-gap technique, showing it blocked neuronal excitability [74].

Figure 3.

Schematic illustration of descending pain pathway and cyclodextrin complexation with monoterpenes (adapted from Quintans-Júnior et al. [24]).

Figure 4.

Structure of terpenes studied for the treatment of FM (adapted from Guimarães et al. [23, 52]).

The possible benefits of the complexation of apolar compounds (such as terpenes) with CDs have been explored by the pharmaceutical industry and by researchers seeking improvements in pharmacological properties such as increased bioavailability, efficacy, and optimization of therapeutic doses (which reduces toxicity and adverse effects) [75, 76]. Clinical and preclinical evidence has shown that the pharmacological effects of analgesic and anti-inflammatory drugs are improved when complexed with CDs [76, 77, 78].

Santos et al. [30] evaluated the effect of citronellal (Figure 4), a monoterpene present in Citrus and Cymbopogon plants, complexed in β-CD as a potential agent against FM symptoms. It was observed that complexation in CD improved the anti-hyperalgesic effect when compared to noncomplexed citronellal. This effect probably involves activation of descending pain pathway areas, such as the PAG and rostroventromedial (RVM) areas, with possible interaction with the glutamate receptors, investigated by a docking study. Citronellal has already presented an antinociceptive effect on capsaicin, glutamate, and formalin-induced orofacial pain, showing that this terpene may be acting via SP and TRPV1 receptors or in the glutamatergic pathway [79]. In addition, the analgesic effect of citronellal was reversed by naloxone in hot-plate tests, which strongly suggests its action on the opioid receptors and its ability to reduce neuronal excitability through blocking sodium channels [51, 79].

Another study, also using the chronic noninflammatory widespread pain model in mice (an FM animal model), evaluated the effect of α-terpineol (Figure 4), both pure and complexed in β-CD, as CDs are useful tools in improving the pharmacological properties of terpenes [77, 80]. The authors observed an anti-hyperalgesic effect, possibly related to the action of α-terpineol on the opioid and serotonergic receptors; visualized with the use of naloxone and ondansetron antagonists; and confirmed by docking studies [31]. Similarly to citronellal, α-terpineol also showed antinociceptive effect in the capsaicin, glutamate, and formalin-induced orofacial nociception tests [81], indicating other possible mechanisms of action of this monoterpene. In summary, it has been shown that monoterpenes complexed in β-cyclodextrin reduce hyperalgesia induced by chronic muscle pain, activating the descending pathway, as described in Figure 3.

Sesquiterpenes occur in nature as hydrocarbons or in oxygenated forms including lactones, alcohols, acids, aldehydes, and ketones. Biosynthesis of sesquiterpenes can occur by the mevalonic acid and the deoxyxylulose phosphate pathway. These compounds have various pharmacological activities including antileishmanial, antimalarial, antifungal, antibacterial, antiviral, anti-inflammatory, and antinociceptive properties and the ability to inhibit the production of nitric oxide and eliminate hydroxyl radicals [82].

β-Caryophyllene (Figure 4) is a bicyclic sesquiterpene compound found in the EO of the Eugenia caryophyllata (cloves) and Piper nigrum (black pepper) plant species. In an experimental study conducted in an FM model in mice, this compound, complexed in β-CD, reduced primary and secondary hyperalgesia as well as inhibited the superficial dorsal horn of the spinal cord, possibly by activation of descending pain pathway [32]. Antagonism studies, in a capsaicin-induced nociception test, showed that the antinociceptive effect of β-caryophyllene was reversed by naloxone, β-funaltrexamine (a μ-opioid receptor antagonist), and AM630 (a CB2 receptor antagonist) [83]. In addition, in a neuropathic pain model, β-caryophyllene had an effect on thermal hyperalgesia and mechanical allodynia, reducing spinal neuroinflammation. The oral administration of β-caryophyllene was more effective than the subcutaneously injected synthetic CB2 agonist JWH-133 [84].

Quintans et al. [33] evaluated the effect of hecogenin acetate (HA), an acetylated steroidal saponin, complexed with β-CD in a chronic noninflammatory widespread pain model. Hecogenin is already used in the pharmaceutical industry to synthesize some oral contraceptive agents. The effect of noncomplexed or complexed HA caused an increase in the nociceptive threshold and primary and secondary hyperalgesia compared to the vehicle control group. However, the HA/β-CD complex was superior in producing an analgesic profile using lower nominal doses of the active principle (HA). In addition, the interaction of the HA with opioid receptors and a decrease in SP levels in the lumbar spinal cord were verified, which indicate participation of this substance in the descending inhibitory pain pathway [33, 85].

The antinociceptive effect of HA was previously observed in the tail-flick test. This effect was reversed by naloxone, CTOP (μ-opioid receptor antagonist), nor-BNI (κ-opioid receptor antagonist), naltrindole (δ-opioid receptor antagonist), and glibenclamide (ATP-sensitive K (+) channel blocker). Mice pretreated with HA had increased neuronal activation in the PAG area, suggesting the participation of the endogenous analgesia pathway in the hecogenin mechanism of action [85].

Some clinical studies with EOs have been developed in humans with FM. O24™ is a blend of six essential oils: aloe vera, eucalyptus, lemon/orange, camphor, rosemary, and peppermint. This mixture is marketed for the relief of pain. In a double-blinded randomized clinical trial, Ko et al. [26] demonstrated the benefits of using this oil, topically, for FM pain relief. Males and females were recruited for the study through newspapers and internet communications. FM diagnosis was confirmed before the patients enrolled in the study. The authors reveal that the main mode of action is as a counterirritant to the pain sensation. The mixture of oils promotes stimulation of A-beta sensory fibers, causing inhibition of the A-delta and C fibers. Moreover, the local effects of O24™ include the inhibition of bradykinin, histamine, and prostaglandins, which do not seem to be directly related to the analgesic effect in FM, so it is more reasonable to propose its effect indirectly in the pathways of pain modulation.

Rutledge and Jones [86] also investigated the topical effect of O24 in a double-blind randomized clinical trial associated with exercises multilevel for 12 weeks. Twenty patients with FM and 23 patients of the sham group were submitted to the study. There was no statistical difference between the groups regarding the pain and physical function, but there was improvement of the physical function, without statistical difference, when compared before and after the treatment, keeping the effect of O24 on the FM symptoms unknown. This result for O24 differs from that described by Ko et al. [26], which may result from the small sample and the type of exercise used, since some exercises may contribute to the maintenance of pain in patients with FM [3].

The effect of Ginkgo biloba extract and the coenzyme Q10 was evaluated in 23 fibromyalgic patients, before and after the treatment, by oral administration, for 12 weeks, with 64% of patients reporting an improvement in quality of life through the application of questionnaires. The improvement observed by these patients may be related in parts to the antioxidant activities described for both coenzyme Q10 and Ginkgo biloba [28].

Due to the properties attributed to capsaicin, Casanueva et al. [34] evaluated the short-term efficacy of topical capsaicin treatment in 130 patients with fibromyalgia who were already using drug therapy. Patients were randomly divided into a control group (same medical treatment that they received before randomization) and topical capsaicin group (medical treatment that they received before randomization + 0.075% capsaicin) by a computer-generated sequence. After 6 weeks, it was observed that the additional topical treatment reduced the myalgia score and improved the quality of life of these patients, showing that capsaicin was also effective in this syndrome.


4. Final considerations

Fibromyalgia is the second most common rheumatologic disorder, being characterized by the manifestation of widespread pain with sensory changes. The treatment strategies for the management of the FM include both pharmacological products (such as duloxetine, pregabalina, and tramadol for pain and amitriptyline, cyclobenzaprine, and pregabalina for sleep disturbance) and non-pharmacological therapies (such as exercise and psychological therapies) [87]. Despite this, fibromyalgia remains difficult to treat and is an important challenge for modern medicine, as the treatments for these conditions are still ineffective with a large number of side effects, making the search for new treatments ever more urgent.

In this context, one important approach to the discovery of new medicines with analgesic activity is research with natural products. For thousands of years, scientists and the pharmaceutical industry have used natural products as a source for new drugs or their precursors, aimed at treating diseases or symptomatology that had no effective treatment. Despite of the animal models described for FM, some limitations can be observed, such as the reversion of the pain with opioid treatment and the absence of other signs and symptoms observed in humans. However, these models are the most resembled FM in humans, being tools used in the search for new treatment options. Nowadays, many natural substances have been studied, clinically and preclinically, for their analgesic potential with respect to fibromyalgia. In this context, essential oils, plant extracts, terpenes, and alkaloids are major sources of natural products.

These substances have been shown to have an analgesic effect in animal models of fibromyalgia, acting through different pathways, including activation of the descending inhibitory pain pathway—specifically the opioid, glutamatergic, cannabinoid, and serotoninergic systems; inhibition of SP in the superficial dorsal horn of the spinal cord; blockage of peripheral fibers; and antioxidant activity. In addition, clinical studies have shown the importance of NPs in the pain management of FM, improving their quality of life. The effective use of these products in the clinic, without reports of considerable adverse effects, describes the advances in the use of NPs in the treatment of FM. These finding make natural products a promising source of treatments for the management of chronic pain.



This work was supported by grants from CNPq (305608/2013-4, 311721/2014-1), CAPES, and FAPITEC/SE (Chamadas Públicas PROMOB e PROEF), all from Brazil. PL Santos, RG Brito, and MA Oliveira were carrying out the master’s or PhD degrees in the Graduate Program in Health Sciences (PPGCS/UFS), and LTS Pina was carrying out the master’s degree in the Graduate Program in Pharmaceutical Sciences (PPGCF/UFS).


  1. 1. Gauffin J, Hankama T, Kautiainen H, Hannonen P, Haanpää M. Neuropathic pain and use of PainDETECT in patients with fibromyalgia: A cohort study. BMC Neurology. 2013 Jan;13:21
  2. 2. Bäckryd E, Tanum L, Lind A-L, Larsson A, Gordh T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. Journal of Pain Research. 2017 Mar;10:515-525
  3. 3. Elvin A, Siösteen A-K, Nilsson A, Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: A contrast media enhanced colour Doppler study. European Journal of Pain. 2006 Feb;10(2):137-144
  4. 4. Calvino B, Grilo RM. Central pain control. Joint, Bone, Spine. 2006 Jan;73(1):10-16
  5. 5. Perl ER. Pain mechanisms: A commentary on concepts and issues. Progress in Neurobiology. 2011 Jun;94(1):20-38
  6. 6. Clauw DJ, Arnold LM, McCarberg BH, FibroCollaborative. The science of fibromyalgia. Mayo Clinic Proceedings. 2011 Sep;86(9):907-911
  7. 7. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seatle: IASP; 1994. 240 p
  8. 8. Mist SD, Firestone KA, Jones KD. Complementary and alternative exercise for fibromyalgia: A meta-analysis. Journal of Pain Research. 2013 Jan;6:247-260
  9. 9. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2005 Apr;52(4):1264-1273
  10. 10. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Practice & Research. Clinical Rheumatology. 2011 Apr;25(2):285-297
  11. 11. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. The Journal of Pain. 2010 Jun;11(6):505-521
  12. 12. Rehm SE, Koroschetz J, Gockel U, Brosz M, Freynhagen R, Tolle TR, et al. A cross-sectional survey of 3035 patients with fibromyalgia: Subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology. 2010 Jun 1;49(6):1146-1152
  13. 13. DeSantana JM, da Cruz KML, Sluka KA. Animal models of fibromyalgia. Arthritis Research & Therapy. 2013;15(6):222
  14. 14. Mogil JS. Animal models of pain: Progress and challenges. Nature Reviews Neuroscience. 2009 Apr;10(4):283-294
  15. 15. Nagakura Y. Recent advancements in animal models of fibromyalgia. MYOPAIN. 2017 Jan 11;1-8
  16. 16. Sluka KA. Is it possible to develop an animal model of fibromyalgia? Pain. 2009 Nov;146(1-2):3-4
  17. 17. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery. 2015 Jan 23;14(2):111-129
  18. 18. Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012 Jan;2(2):303-336
  19. 19. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. Journal of Natural Products. 2011 Jun 24;74(6):1539-1555
  20. 20. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971 Jun 23;231(25):232-235
  21. 21. Goerig M, Schulte am Esch J. [Friedrich Wilhelm Adam Sertürner—the discoverer of morphine]. Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 1991 Dec;26(8):492-498
  22. 22. McCurdy CR, Scully SS. Analgesic substances derived from natural products (natureceuticals). Life Sciences. 2005 Dec 22;78(5):476-484
  23. 23. Guimarães AG, Serafini MR, Quintans-Júnior LJ. Terpenes and derivatives as a new perspective for pain treatment: A patent review. Expert Opinion on Therapeutic Patents. 2014 Mar;24(3):243-265
  24. 24. Quintans-Júnior LJ, Brito RG, Quintans JSS, Santos PL, Camargo ZT, Barreto PA, et al. Nanoemulsion thermoreversible pluronic F127-based hydrogel containing Hyptis pectinata (Lamiaceae) leaf essential oil produced a lasting anti-hyperalgesic effect in chronic noninflammatory widespread pain in mice. Molecular Neurobiology. 2017 Feb 13
  25. 25. Nascimento SS, Araújo AAS, Brito RG, Serafini MR, Menezes PP, DeSantana JM, et al. Cyclodextrin-complexed Ocimum basilicum leaves essential oil increases Fos protein expression in the central nervous system and produce an antihyperalgesic effect in animal models for fibromyalgia. International Journal of Molecular Sciences. 2015 Jan;16(1):547-563
  26. 26. Ko GD, Hum A, Traitses G, Berbrayer D. Effects of topical O24 essential oils on patients with fibromyalgia syndrome: A randomized, placebo controlled pilot study. Journal of Musculoskeletal Pain. 2007 Jan 16;15(1):11-19
  27. 27. Chopade AR, Sayyad FJ. Antifibromyalgic activity of standardized extracts of Phyllanthus amarus and Phyllanthus fraternus in acidic saline induced chronic muscle pain. Biomedicine and Aging Pathology. 2014 Apr;4(2):123-130
  28. 28. Lister R. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo Biloba extract in fibromyalgia syndrome. The Journal of International Medical Research. 2002 Apr;30(2):195-199
  29. 29. Nascimento SS, Camargo EA, DeSantana JM, Araújo AAS, Menezes PP, Lucca-Júnior W, et al. Linalool and linalool complexed in β-cyclodextrin produce anti-hyperalgesic activity and increase Fos protein expression in animal model for fibromyalgia. Naunyn Schmiedebergs Archives of Pharmacology. 2014 Jun 24
  30. 30. Santos PL, Brito RG, Oliveira MA, Quintans JSS, Guimarães AG, Santos MR V, et al. Docking, characterization and investigation of β-cyclodextrin complexed with citronellal, a monoterpene present in the essential oil of Cymbopogon species, as an anti-hyperalgesic agent in chronic muscle pain model. Phytomedicine. 2016 Aug 15;23(9):948-957
  31. 31. Oliveira MGB, Brito RG, Santos PL, Araújo-Filho HG, Quintans JSS, Menezes PP, et al. α-Terpineol, a monoterpene alcohol, complexed with β-cyclodextrin exerts antihyperalgesic effect in animal model for fibromyalgia aided with docking study. Chemico-Biological Interactions. 2016 Jul 25;254:54-62
  32. 32. Quintans-Júnior LJ, Araújo AAS, Brito RG, Santos PL, Quintans JSS, Menezes PP, et al. β-Caryophyllene, a dietary cannabinoid, complexed with β-cyclodextrin produced antihyperalgesic effect involving the inhibition of Fos expression in superficial dorsal horn. Life Sciences. 2016 Mar;149:34-41
  33. 33. Quintans JSS, Pereira EWM, Carvalho YMBG, Menezes PP, Serafini MR, Batista MVA, et al. Host-guest inclusion complexation of β-cyclodextrin and hecogenin acetate to enhance anti-hyperalgesic effect in an animal model of musculoskeletal pain. Process Biochemistry. 2016 Aug;52:1-15
  34. 34. Casanueva B, Rodero B, Quintial C, Llorca J, González-Gay MA. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatology International. 2013 Oct 28;33(10):2665-2670
  35. 35. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle & Nerve. 2001 Jan;24(1):37-46
  36. 36. Dina OA, Levine JD, Green PG. Muscle inflammation induces a protein kinase Cε-dependent chronic-latent muscle pain. The Journal of Pain. 2008 May;9(5):457-462
  37. 37. Dina OA, Green PG, Levine JD. Role of interleukin-6 in chronic muscle hyperalgesic priming. Neuroscience. 2008 Mar 18;152(2):521-525
  38. 38. Yokoyama T, Lisi TL, Moore SA, Sluka KA. Muscle fatigue increases the probability of developing hyperalgesia in mice. The Journal of Pain. 2007 Sep;8(9):692-699
  39. 39. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain. 2009 Nov;146(1):26-33
  40. 40. Nishiyori M, Uchida H, Nagai J, Araki K, Mukae T, Kishioka S, et al. Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants. Molecular Pain. 2011 Sep 21;7:69
  41. 41. Khasar SG, Dina OA, Green PG, Levine JD. Sound stress-induced long-term enhancement of mechanical hyperalgesia in rats is maintained by sympathoadrenal catecholamines. The Journal of Pain. 2009 Oct;10(10):1073-1077
  42. 42. Azmir J, Zaidul ISM, Rahman MM, Sharif KM, Mohamed A, Sahena F, et al. Techniques for extraction of bioactive compounds from plant materials: A review. Journal of Food Engineering. 2013 Aug;117(4):426-436
  43. 43. Tongnuanchan P, Benjakul S. Essential oils: Extraction, bioactivities, and their uses for food preservation. Journal of Food Science. 2014 Jul;79(7):R1231-R1249
  44. 44. de Souza Nascimento S, Desantana JM, Nampo FK, Ribeiro EAN, da Silva DL, Araújo-Júnior JX, et al. Efficacy and safety of medicinal plants or related natural products for fibromyalgia: A systematic review. Evidence-based Complementary and Alternative Medicine. 2013;2013:149468
  45. 45. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils—A review. Food and Chemical Toxicology. 2008 Feb;46(2):446-475
  46. 46. Nikolić B, Vasilijević B, Mitić-Ćulafić D, Vuković-Gačić B, Knežević-Vukćević J. Comparative study of genotoxic, antigenotoxic and cytotoxic activities of monoterpenes camphor, eucalyptol and thujone in bacteria and mammalian cells. Chemico-Biological Interactions. 2015 Dec 5;242:263-271
  47. 47. Caldas GFR, Limeira MMF, Araújo AV, Albuquerque GS, Silva-Neto JD, Silva TG, et al. Repeated-doses and reproductive toxicity studies of the monoterpene 1,8-cineole (eucalyptol) in Wistar rats. Food and Chemical Toxicology. 2016 Nov;97:297-306
  48. 48. Gautam LN, Ling T, Lang W, Rivas F. Anti-proliferative evaluation of monoterpene derivatives against leukemia. European Journal of Medicinal Chemistry. 2016 May 4;113:75-80
  49. 49. Oz M, Lozon Y, Sultan A, Yang K-HS, Galadari S. Effects of monoterpenes on ion channels of excitable cells. Pharmacology & Therapeutics. 2015 Aug;152:83-97
  50. 50. Brito RG, Guimarães AG, Quintans JSS, Santos MRV, De Sousa DP, Badaue-Passos D, et al. Citronellol, a monoterpene alcohol, reduces nociceptive and inflammatory activities in rodents. Journal of Natural Medicines. 2012 Oct;66(4):637-644
  51. 51. Melo MS, Sena LCS, Barreto FJN, Bonjardim LR, Almeida JRGS, Lima JT, et al. Antinociceptive effect of citronellal in mice. Pharmaceutical Biology. 2010 Apr;48(4):411-416
  52. 52. Guimarães AG, Quintans JSS, Quintans LJJ. Monoterpenes with analgesic activity—A systematic review. Phytherapy Research PTR. 2013 Jan;27(1):1-15
  53. 53. Dixon RA, Pasinetti GM. Flavonoids and isoflavonoids: From plant biology to agriculture and neuroscience. Plant Physiology. 2010 Oct 1;154(2):453-457
  54. 54. Moses T, Papadopoulou KK, Osbourn A. Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives. Critical Reviews in Biochemistry and Molecular Biology. 2014 Nov 6;49(6):439-462
  55. 55. Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. Journal of Ethnopharmacology. 2004 Oct;94(2-3):219-243
  56. 56. Cushnie TPT, Cushnie B, Lamb AJ. Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities. International Journal of Antimicrobial Agents. 2014 Nov;44(5):377-386
  57. 57. Hesse M. Alkaloids : Nature’s Curse or Blessing? Verlag Helvetica Chimica Acta; 2002. 413 p
  58. 58. Hraiech S, Bregeon F, Brunel J-M, Rolain J-M, Lepidi H, Andrieu V, et al. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. The Journal of Antimicrobial Chemotherapy. 2012 Oct 1;67(10):2452-2458
  59. 59. Bogatcheva E, Hanrahan C, Nikonenko B, de los Santos G, Reddy V, Chen P, et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorganic & Medicinal Chemistry Letters. 2011 Sep 15;21(18):5353-5357
  60. 60. Parhi A, Kelley C, Kaul M, Pilch DS, LaVoie EJ. Antibacterial activity of substituted 5-methylbenzo[c]phenanthridinium derivatives. Bioorganic & Medicinal Chemistry Letters. 2012 Dec 1;22(23):7080-7083
  61. 61. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: Parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999 May;81(1-2):135-145
  62. 62. Morgenlander JC, Hurwitz BJ, Massey EW. Cabsaicin for the trunent of pain in Guillain-Barré syndrome. Annals of Neurology. 1990 Aug;28(2):199
  63. 63. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004 Apr 24;328(7446):991
  64. 64. Lisboa ACCD, Mello ICM, Nunes RS, Dos Santos MA, Antoniolli AR, Marçal RM, et al. Antinociceptive effect of Hyptis pectinata leaves extracts. Fitoterapia. 2006 Sep;77(6):439-442
  65. 65. Raymundo LJRP, Guilhon CC, Alviano DS, Matheus ME, Antoniolli AR, Cavalcanti SCH, et al. Characterisation of the anti-inflammatory and antinociceptive activities of the Hyptis pectinata (L.) Poit essential oil. Journal of Ethnopharmacology. 2011 Apr 12;134(3):725-732
  66. 66. Venâncio AM, Marchioro M, Estavam CS, Melo MS, Santana MT, Onofre ASC, et al. Ocimum basilicum leaf essential oil and (−)-linalool reduce orofacial nociception in rodents: A behavioral and electrophysiological approach. Revista Brasileira Farmacognosia. 2011 Dec;21(6):1043-1051
  67. 67. Venâncio AM, Onofre AS, Lira AF, Alves PB, Blank AF, Antoniolli AR, et al. Chemical composition, acute toxicity, and antinociceptive activity of the essential oil of a plant breeding cultivar of basil (Ocimum basilicum L.). Planta Medica. 2011 May;77(8):825-829
  68. 68. Chopade A, Sayyad F. Analysis of the mechanisms underlying the analgesic effects of the extracts of Phyllanthus amarus & Phyllanthus fraternus. Asian Journal of Pharmaceutical Research. 2013;1(2):34-39
  69. 69. Chopade A, Sayyad F. Toxicity studies and evaluation of Phyllanthus amarus and Phyllanthus fraternus extracts on the central nervous system and musculoskeletal function. International Journal of Pharmaceutical, Chemistry Science. 2013;2:1333-1338
  70. 70. Peana AT, D’Aquila PS, Chessa ML, Moretti MDL, Serra G, Pippia P. (−)-Linalool produces antinociception in two experimental models of pain. European Journal of Pharmacology. 2003 Jan 26;460(1):37-41
  71. 71. Batista PA, de Paula Werner MF, Oliveira EC, Burgos L, Pereira P, da Silva Brum LF, et al. The antinociceptive effect of (−)-linalool in models of chronic inflammatory and neuropathic hypersensitivity in mice. The Journal of Pain. 2010 Nov;11(11):1222-1229
  72. 72. Berliocchi L, Russo R, Levato A, Fratto V, Bagetta G, Sakurada S, et al. Chapter 17 (−)-linalool attenuates allodynia in neuropathic pain induced by spinal nerve ligation in C57/Bl6 mice. In: International Review of Neurobiology. 2009. pp. 221-235
  73. 73. Batista PA, Werner MF, Oliveira EC, Burgos L, Pereira P, Brum LF, et al. Evidence for the involvement of ionotropic glutamatergic receptors on the antinociceptive effect of (−)-linalool in mice. Neuroscience Letters. 2008 Aug 8;440(3):299-303
  74. 74. de Almeida RN, Araújo DAM, Gonçalves JCR, Montenegro FC, de Sousa DP, Leite JR, et al. Rosewood oil induces sedation and inhibits compound action potential in rodents. Journal of Ethnopharmacology. 2009 Jul 30;124(3):440-443
  75. 75. Lima PSS, Lucchese AM, Araújo-Filho HG, Menezes PP, Araújo AAS, Quintans-Júnior LJ, et al. Inclusion of terpenes in cyclodextrins: Preparation, characterization and pharmacological approaches. Carbohydrate Polymers 2016 Oct 20;151:965-987
  76. 76. Santos PL, Brito RG, Quintans JSS, Araújo AAS, Menezes IRA, Brogden NK, et al. Cyclodextrins as encapsulation agents to improve the anti-inflammatory drugs profile: A systematic review and meta-analysis. Current Pharmaceutical Design. 2017 Jan 26
  77. 77. Brito RG, Araújo AAS, Quintans JSS, Sluka KA, Quintans Júnior LJ. Enhanced analgesic activity by cyclodextrins—A systematic review and meta-analysis. Expert Opinion on Drug Delivery. 2015
  78. 78. Oliveira MGB, Guimarães AG, Araújo AAS, Quintans JSS, Santos MR V, Quintans-Júnior LJ. Cyclodextrins: Improving the therapeutic response of analgesic drugs: A patent review. Expert Opinion on Therapeutic Patents. 2015 Jan;25(8):897-907
  79. 79. Quintans-Júnior LJ, Melo MS, De Sousa DP, Araujo AAS, Onofre ACS, Gelain DP, et al. Antinociceptive effects of citronellal in formalin-, capsaicin-, and glutamate-induced orofacial nociception in rodents and its action on nerve excitability. Journal of Orofacial Pain. 2010 Jan;24(3):305-312
  80. 80. Lima PSS, Lucchese AM, Araújo-Filho HG, Menezes PP, Araújo AAS, Quintans-Júnior LJ, et al. Inclusion of terpenes in cyclodextrins: Preparation, characterization and pharmacological approaches. Carbohydrate Polymers. 2016;151:965-987
  81. 81. Quintans-Júnior LJ, Oliveira MGB, Santana MF, Santana MT, Guimarães AG, Siqueira JS, et al. α-Terpineol reduces nociceptive behavior in mice. Pharmaceutical Biology. 2011 Jun 8;49(6):583-586
  82. 82. Awouafack MD, Tane P, Kuete V, Eloff JN. Sesquiterpenes from the medicinal plants of Africa. In: Medicinal Plant Research in Africa. Elsevier; 2013. pp. 33-103
  83. 83. Katsuyama S, Mizoguchi H, Kuwahata H, Komatsu T, Nagaoka K, Nakamura H, et al. Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. European Journal of Pain. 2013 May;17(5):664-675
  84. 84. Klauke A-L, Racz I, Pradier B, Markert A, Zimmer AM, Gertsch J, et al. The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. European Neuropsychopharmacology. 2014 Apr;24(4):608-620
  85. 85. Gama KB, Quintans JSS, Antoniolli ÂR, Quintans-Júnior LJ, Santana WA, Branco A, et al. Evidence for the involvement of descending pain-inhibitory mechanisms in the antinociceptive effect of Hecogenin Acetate. Journal of Natural Products. 2013 Apr 26;76(4):559-563
  86. 86. Rutledge DN, Jones CJ. Effects of topical essential oil on exercise volume after a 12-week exercise program for women with fibromyalgia: A pilot study. Journal of Alternative and Complementary Medicine. 2007 Dec;13(10):1099-1106
  87. 87. Ablin J, Fitzcharles M-A, Buskila D, Shir Y, Sommer C, Häuser W. Treatment of fibromyalgia syndrome: Recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence-Based Complementary and Alternative Medicine eCAM. 2013;2013:485272

Written By

Renan Guedes Brito, Priscila Laise Santos, Marlange Almeida Oliveira, Lícia Tairiny Santos Pina, Angelo Roberto Antoniolli, Jackson Roberto Guedes da Silva Almeida, Laurent Picot, Gokhan Zengin, Jullyana Souza Siqueira Quintans and Lucindo José Quintans Júnior

Submitted: 05 December 2016 Reviewed: 05 June 2017 Published: 20 December 2017